Quantification in respiratory-gated PET acquisition: can data-driven methods replace device-based systems?-a comparative and retrospective study.

IF 3.1 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

EJNMMI Research Pub Date : 2025-02-14 DOI:10.1186/s13550-025-01195-w

Laurentiu Agrigoroaie, Nadege Anizan, Camilo Garcia, Corinne Balleyguier, Théophraste Henry

{"title":"Quantification in respiratory-gated PET acquisition: can data-driven methods replace device-based systems?-a comparative and retrospective study.","authors":"Laurentiu Agrigoroaie, Nadege Anizan, Camilo Garcia, Corinne Balleyguier, Théophraste Henry","doi":"10.1186/s13550-025-01195-w","DOIUrl":null,"url":null,"abstract":"Background: Device-based respiratory gating improves diagnostic and quantification accuracy in positron emission tomography (PET), but requires additional time to setup the device and the failure rate can be significant. Our aim was to internally validate the quantification performance of data-driven respiratory-gated PET imaging against the gold standard, the device-based method, in clinical oncological practice. We retrospectively analysed [18F]FDG PET/CT scans of patients from our centre with at least one measurable [18F]FDG-avid malignant lesion. All PET/CT acquisitions were performed on a Siemens Biograph 64 Vision 600 system with respiratory gating by belt and also by adding the data-driven gating with OncoFreeze AI™. We recorded the SUVmax and SUVpeak for up to a maximum of 5 lesions per patient. We computed the mean absolute bias between the two gating methods and the 95% confidence intervals (CI) at the cohort level and in subgroups.Results: Of the 692 consecutive patients screened for inclusion, 196 patients were analysed, from whom 536 lesions were measured. The mean absolute biases in the SUVmax and SUVpeak of lesions in the whole cohort were 3.8% (CI 3.4-4.2) and 2.1% (CI 1.9-2.4), respectively. At patient-level, 21% of them had at least one lesion with a SUVmax bias above 10%, while for SUVpeak this proportion was 5%. In the subgroup analysis by PERCIST criteria, only 2% of patients had significant bias in the SUVmax, and 0.5% in SUVpeak. There was no clinically significant effect of lesion size or anatomical site on SUV measurements between the two respiratory gating methods.Conclusion: Quantitative comparison of data-driven and device-based respiratory-gated PET scans revealed negligible differences, proving that data-driven respiratory gating is a reliable and accurate alternative to the device-based gating method in routine [18F]FDG-PET/CT oncological evaluation.","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"9"},"PeriodicalIF":3.1000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11828764/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-025-01195-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Device-based respiratory gating improves diagnostic and quantification accuracy in positron emission tomography (PET), but requires additional time to setup the device and the failure rate can be significant. Our aim was to internally validate the quantification performance of data-driven respiratory-gated PET imaging against the gold standard, the device-based method, in clinical oncological practice. We retrospectively analysed [18F]FDG PET/CT scans of patients from our centre with at least one measurable [18F]FDG-avid malignant lesion. All PET/CT acquisitions were performed on a Siemens Biograph 64 Vision 600 system with respiratory gating by belt and also by adding the data-driven gating with OncoFreeze AI™. We recorded the SUVmax and SUVpeak for up to a maximum of 5 lesions per patient. We computed the mean absolute bias between the two gating methods and the 95% confidence intervals (CI) at the cohort level and in subgroups.

Results: Of the 692 consecutive patients screened for inclusion, 196 patients were analysed, from whom 536 lesions were measured. The mean absolute biases in the SUVmax and SUVpeak of lesions in the whole cohort were 3.8% (CI 3.4-4.2) and 2.1% (CI 1.9-2.4), respectively. At patient-level, 21% of them had at least one lesion with a SUVmax bias above 10%, while for SUVpeak this proportion was 5%. In the subgroup analysis by PERCIST criteria, only 2% of patients had significant bias in the SUVmax, and 0.5% in SUVpeak. There was no clinically significant effect of lesion size or anatomical site on SUV measurements between the two respiratory gating methods.

Conclusion: Quantitative comparison of data-driven and device-based respiratory-gated PET scans revealed negligible differences, proving that data-driven respiratory gating is a reliable and accurate alternative to the device-based gating method in routine [18F]FDG-PET/CT oncological evaluation.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-

CiteScore

5.90

自引率

3.10%

发文量

审稿时长

13 weeks

期刊介绍： EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.